Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection-Reference-Cited by-同舟云学术

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

Published:2017-11-02 Issue:5-6 Volume:18 Page:189-195
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Yong Chan-Loi¹,Gathe Joseph C.²,Knecht Gabriele³,Orrell Catherine⁴^ORCID,Mallolas Josep⁵,Podzamczer Daniel⁶,Trottier Benoit⁷^ORCID,Zhang Wei¹,Sabo John P.¹,Vinisko Richard¹^ORCID,Drulak Murray¹,Quinson Anne-Marie¹

Affiliation:

1. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

2. Therapeutic Concepts, Houston, TX, USA

3. Infektiologikum, Frankfurt, Germany

4. Desmond Tutu HIV Foundation, Observatory, Cape Town, South Africa

5. Hospital Clínic-University of Barcelona, Barcelona, Spain

6. Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

7. Clinique médicale l’Actuel, Montreal, Canada

Funder

Boehringer Ingelheim

Publisher

Informa UK Limited